Click here for slides on this topic


IMPROVE-IT

Double-blind, randomized trial of 18,144 individuals with ACS who were assigned combination simvastatin + ezetimbe or simvastatin alone to determine whether ezetimibe had an effect on a composite of cardiovascular death, myocardial infarction, documented unstable angina requiring hospitalization, coronary revascularization after 1 month of treatment, or stroke.
The following content matched the glossary term: IMPROVE-IT

NDEI.org Expert Commentary Silvio Inzucchi MD on IMPROVE-IT Subanalysis CV Benfits of Ezetimibe Exclusive to Subjects With Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of IMPROVE-IT that showed the cardiovascular benefits of ezetimibe are restricted to patients with type 2 diabetes; from ESC Congress 2015.

CV Benefits of Ezetimibe Favor Patients With Type 2 Diabetes in IMPROVE-IT Analysis

Top

Data from a subanalysis of IMPROVE-IT at ESC Congress 2015 show that the cardiovascular benefits of ezetimibe are exclusive to individuals with type 2 diabetes. Includes expert commentary.



Slide Library Results

Search Results for: IMPROVE-IT Slides Found: 56
Opportunities and Challenges for Care Extended Family Roles
Encourage Family Involvement to Improve Compliance
DCCT/EDIC: Incidence of Any Cardiovascular Disease Outcome
DCCT/EDIC: Incidence of Nonfatal MI, Stroke, or Death
Hypothetical Outcomes of Interventions to Prevent Type 2 Diabetes
STAMPEDE: Design
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
ACP: Recommendations for Oral Pharmacologic Therapy for Type 2 Diabetes
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN: Design
CONQUER: Design
CONQUER: Randomization and Endpoints
CONQUER Co-Primary Outcome: Change in Body Weight
CONQUER Co-Primary Outcome: Proportion of Subjects Achieving ≥5% Weight Loss
CONQUER: Secondary Outcomes and Adverse Events
Bariatric Surgery for Obesity
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (1 of 2)
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
HPS2-THRIVE: Niacin and Vascular Risk
ESH/ESC Hypertension Guidelines: Hypertension Treatment for People With Metabolic Syndrome
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
ADA Nutrition Guidelines: Nutrition Therapy
ADA Nutrition Guidelines: Energy Balance
ADA Nutrition Guidelines: Protein
ADA Nutrition Guidelines: Fats
ADA Nutrition Guidelines: Micronutrients, Herbal Supplements
SGLT2 Dapagliflozin + Insulin Type 1 Diabetes Treatment Slide | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
ACCORD BP Post-hoc Analysis: Primary Outcome by Waist/Height Quartiles
AACE 2015 Diabetes Guidelines Lifestyle Changes Diet Exercise PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring CGM SMBG PPT | NDEI
Bariatric Surgery for Weight Loss in Type 2 Diabetes for CVD Prevention | NDEI
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
ACCORD BP Post-hoc Analysis: Design
ACCORD BP Post-hoc Analysis: Secondary Outcomes by Waist/Height Quartiles
ACCORD BP Post-hoc Analysis:Outcomes by Treatment Group, Waist-to-Height Quartiles
ADA Obesity Management Guidelines in Patients With Type 2 Diabetes | NDEI
Adjunctive Therapies for Diabetic Foot Wound Care Guidelines PPT | NDEI
Preoperative Workup Metabolic Surgery for Type 2 Diabetes Treatment | NDEI